Sunday, November 24, 2024

Safeguarding the brain from oxidative damage

›
Kyung Hee Lee, Un Jeng Kim, Bae Hwan Lee, Myeounghoon Cha, Safeguarding the brain from oxidative damage, Free Radical Biology and Medicine, ...

Exploring neuropsychiatric symptoms in Friedreich ataxia

›
Karamazovova, S., Stovickova, L., Jester, D.J. et al. Exploring neuropsychiatric symptoms in Friedreich ataxia. Sci Rep 14, 29076 (2024). do...
Saturday, November 23, 2024

Ferroptosis—disease perils and therapeutic promise

›
Ashley R. Brown et al. ,Ferroptosis—disease perils and therapeutic promise.Science386,848-849(2024).DOI:10.1126/science.adn703  Identifying ...

Therapeutic Activity of a Haematopoietic Stem Cell-Delivered Tissue-Penetrating Peptide in Friedreich's Ataxia Models

›
Pido, Jeffrey and Shaban, Enas and Moula, Shefta and Chritchely, Bethan and Whittaker, Thomas and Svensson, Stina and Anjomani Virmouni, Sar...
Thursday, November 21, 2024

Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

›
BALA CYNWYD, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology comp...
Saturday, November 9, 2024

Precision medicine and Friedreich ataxia: promoting equity, beneficence, and informed consent for novel gene therapies

›
Kwa, F., Kendal, E. Precision medicine and Friedreich ataxia: promoting equity, beneficence, and informed consent for novel gene therapies. ...
Friday, November 8, 2024

frataxin is essential for zebrafish embryogenesis and pronephros formation

›
frataxin is essential for zebrafish embryogenesis and pronephros formation. Wesley S. Ercanbrack, Austin Dungan, Ella Gaul, Mateo Ramirez, R...

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

›
WARREN, N.J., Nov. 7, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. "We continue to achieve excellent revenue performance allowing us to ...

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

›
CARLSBAD, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) Friedreich Ataxia (FA) Design is on track to initiate the Phase 1 single ascending dose, no...

Abnormal visual cortex activity using functional magnetic resonance imaging in treatment resistant photophobia in Friedreich Ataxia

›
Araliya N. Gunawardene, Nicholas Reyes, David Valdes-Arias, Alpen Ortug, Jaime Martinez, Anat Galor, Eric A. Moulton, Abnormal visual cortex...